TAK NYSE Pharmaceutical Preparations Financials FY2017–FY2026
Takeda Pharmaceutical Co Ltd had $29.9B of revenue in fiscal 2026, down 0.5% on the year before. Over five years, revenue changed −0.2% a year on average.
Last close · Oct 30, 2026
$20.91
+$7.68 (+58.05%) past year
Hi! I read Takeda Pharmaceutical Co Ltd’s latest annual report (fiscal 2026). Here is what stands out:
Good So-so Weak
Are sales growing?
−0.5%
No. Sales fell 0.5% last year.
Does it make a profit?
−3.4%
No. It lost money last year.
Does profit turn into cash?
19.2%
Yes. 19.2% of sales ends up as free cash.
Is debt under control?
5.6x
Heavy. Repaying its debt would take 5.6 years of operating profit.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA summarises the numbers
Takeda Pharmaceutical Co Ltd had $29.9B of revenue in fiscal 2026, down 0.5% on the year before.
Over five years, revenue changed −0.2% a year on average.
Its operating margin was 0.1%, down 7.3 pts: of every 100 in sales, about 0 is left after running the business.
Revenue
Margins, % of revenue
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Loss periods are shown in red.
KIRA summarises the numbers
Takeda Pharmaceutical Co Ltd lost $1.0B in fiscal 2026.
Net income
Diluted EPS
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
KIRA summarises the numbers
Free cash flow was $5.7B in fiscal 2026, 19.2% of revenue.
Free cash flow
Cash from operations vs capital spending
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
KIRA summarises the numbers
Takeda Pharmaceutical Co Ltd returned $2.4B to shareholders in fiscal 2026, 42% of free cash flow.
The diluted share count fell 1.9%.
Dividends and buybacks
Diluted shares outstanding (annual)
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
KIRA summarises the numbers
In the last 12 months, insiders sold $13.1M of shares on the open market and bought none.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$13.1M
13 insiders
Of sales under plans
19%
$2.5M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | Lauren Rusckowski DupreyChief Transformation Officer | Sold | 34,535 | $18.54 | $0.6M | Form 4 |
| Sep 2, 2026 | Andrew Stewart PlumpPresident, R&D, Director | Sold plan | 116,191 | $18.49 | $2.1M | Form 4 |
| Aug 19, 2026 | Andrew Stewart PlumpPresident, R&D, Director | Sold plan | 19,651 | $18.49 | $0.4M | Form 4 |
| Aug 18, 2026 | Nicola Deidre Petal GreenwayChief Human Resources Officer | Sold | 12,980 | $18.11 | $0.2M | Form 4 |
| Aug 11, 2026 | Elaine Mary ShannonPres., Global Supply & Quality | Sold | 20,363 | $17.55 | $0.4M | Form 4 |
| Aug 10, 2026 | Julie So-Young KimPresident and CEO, Director | Sold | 89,090 | $17.10 | $1.5M | Form 4 |
| Aug 10, 2026 | Teresa Marie BitettiPresident, OBU | Sold | 50,012 | $17.10 | $0.9M | Form 4 |
| Aug 10, 2026 | Rhonda Janice PachecoPresident, U.S. Business Unit | Sold | 16,901 | $17.10 | $0.3M | Form 4 |
| Aug 10, 2026 | Ramy Riad Ahmed IbrahimPresident, PDT BU | Sold | 7,277 | $17.10 | $0.1M | Form 4 |
| Aug 10, 2026 | Nicola Deidre Petal GreenwayChief Human Resources Officer | Sold | 6,774 | $17.10 | $0.1M | Form 4 |
| Aug 10, 2026 | Nicola Deidre Petal GreenwayChief Human Resources Officer | Sold | 34,603 | $17.51 | $0.6M | Form 4 |
| Aug 10, 2026 | Natalie Anne Marie FurneyGlobal General Counsel | Sold | 30,868 | $17.10 | $0.5M | Form 4 |
| Aug 10, 2026 | Lauren Rusckowski DupreyChief Transformation Officer | Sold | 47,586 | $17.10 | $0.8M | Form 4 |
| Aug 10, 2026 | Agosti Marcello PignagnoliHead, Strat. & Port. Dev | Sold | 22,957 | $17.10 | $0.4M | Form 4 |
| Aug 10, 2026 | Giles Richard PlatfordPresident, IBU | Sold | 31,083 | $17.10 | $0.5M | Form 4 |
| Aug 10, 2026 | Gabriele RicciChief Data & Tech. Officer | Sold | 25,088 | $17.10 | $0.4M | Form 4 |
| Aug 10, 2026 | Elaine Mary ShannonPres., Global Supply & Quality | Sold | 3,978 | $17.10 | $0.1M | Form 4 |
| Aug 10, 2026 | Awny Samaan Botros FarajallahChief Medical Officer | Sold | 14,006 | $17.10 | $0.2M | Form 4 |
| Aug 10, 2026 | Andrew Stewart PlumpPresident, R&D, Director | Sold | 165,393 | $17.10 | $2.8M | Form 4 |
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Takeda Pharmaceutical Co Ltd can carry it.
KIRA summarises the numbers
Takeda Pharmaceutical Co Ltd owes $26.9B more than it holds in cash, about 5.6 years of operating profit.
Cash vs debt (incl. leases)
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | $7.0B | $4.0B | $3.0B | $2.6B | $3.7B |
| Debt incl. finance leases | $35.7B | $32.9B | $32.0B | $30.2B | $30.6B |
| Net debt / EBITDA | 3.1x | 3.4x | 4.5x | 3.8x | 5.6x |
| Debt / equity | 0.8x | 0.7x | 0.7x | 0.7x | 0.7x |
| Interest coverage | 3.8x | 4.2x | 1.8x | 2.5x | 0.0x |
| Current ratio | 1.2x | 1.0x | 1.1x | 1.0x | 1.1x |
| Quick ratio | 0.8x | 0.6x | 0.6x | 0.5x | 0.6x |
| Total assets | $108.2B | $104.8B | $99.9B | $95.4B | $97.3B |
| Total liabilities | $61.5B | $57.1B | $51.8B | $48.9B | $50.7B |
| Shareholders' equity | $46.7B | $47.7B | $48.1B | $46.4B | $46.6B |
| Net debt (− = net cash) | $28.7B | $28.9B | $29.0B | $27.6B | $26.9B |
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
KIRA summarises the numbers
Its return on capital was 0.0%: every 100 invested in the business earned about 0 in a year.
Return on capital, equity and assets (annual)
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
KIRA summarises the numbers
Takeda Pharmaceutical Co Ltd passes 5 of 9 financial health tests (Piotroski F-score).
| Test | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| F-score | 6 / 9 | 7 / 9 | 5 / 9 | 5 / 9 | 5 / 9 |
| Accruals ratio | −7.1% | −4.6% | −3.9% | −6.4% | −8.2% |
| Altman Z'' | 1.64 | 1.43 | 1.48 | 1.43 | 1.23 |
| Net income is positive | ✓ | ✓ | ✓ | ✓ | ✕ |
| Cash from operations is positive | ✓ | ✓ | ✓ | ✓ | ✓ |
| Return on assets rose | ✕ | ✓ | ✕ | ✕ | ✕ |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ | ✓ | ✓ |
| Debt fell relative to assets | ✓ | ✓ | ✕ | ✓ | ✓ |
| Current ratio rose | ✕ | ✕ | ✓ | ✕ | ✓ |
| Share count didn't rise | ✕ | ✓ | ✕ | ✕ | ✓ |
| Gross margin rose | ✓ | ✓ | ✕ | ✕ | ✕ |
| Revenue rose relative to assets | ✓ | ✕ | ✓ | ✓ | ✕ |
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
Every number, year by year.
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $16.0B | $16.0B | $18.9B | $30.3B | $30.2B | $31.8B | $29.7B | $29.5B | $30.1B | $29.9B |
| Gross profit | $10.8B | $11.5B | $13.0B | $20.3B | $20.8B | $21.9B | $20.5B | $19.6B | $19.7B | $19.5B |
| Research and development | $2.9B | $2.9B | $3.3B | $4.5B | $4.3B | $4.7B | $4.7B | $5.1B | $4.8B | $4.5B |
| Operating income | $1.4B | $2.2B | $2.1B | $924M | $4.8B | $4.1B | $3.6B | $1.5B | $2.2B | $41.2M |
| Interest expense | $69.8M | $90.5M | $434M | $1.4B | $1.2B | $1.1B | $863M | $827M | $901M | $983M |
| Pretax income | $1.3B | $2.0B | $1.2B | −$559M | $3.5B | $2.7B | $2.8B | $365M | $1.1B | −$944M |
| Income tax | $257M | $275M | −$67.3M | −$966M | −$93.7M | $644M | $429M | −$632M | $439M | $64.8M |
| Net income | $1.1B | $1.7B | $1.2B | $407M | $3.5B | $2.0B | $2.3B | $997M | $708M | −$1.0B |
| Net income to common | $1.1B | $1.7B | $1.2B | $407M | $3.5B | $2.0B | $2.3B | $997M | $708M | −$1.0B |
| Diluted EPS | $0.67 | $1.07 | $0.63 | $0.13 | $1.13 | $0.65 | $0.75 | $0.32 | $0.22 | −$0.32 |
| Diluted shares | 1.57B | 1.57B | 1.93B | 3.13B | 3.15B | 3.15B | 3.14B | 3.16B | 3.21B | 3.15B |
| Cash flow | ||||||||||
| Cash from operations | $2.4B | $3.4B | $3.0B | $6.2B | $9.5B | $10.0B | $7.2B | $5.0B | $6.9B | $6.9B |
| Capital expenditure | $569M | $604M | $700M | $1.2B | $1.0B | $1.1B | $1.0B | $1.2B | $1.3B | $1.2B |
| Free cash flow | $1.8B | $2.8B | $2.3B | $5.0B | $8.5B | $8.9B | $6.2B | $3.7B | $5.6B | $5.7B |
| Depreciation and amortization | $1.6B | $1.6B | $2.2B | $5.4B | $5.3B | $5.2B | $4.9B | $5.0B | $5.0B | $4.8B |
| Acquisitions | $5.4B | $256M | $26.7B | $45.0M | $0.0M | $442M | $0.0M | $0.0M | — | — |
| Share buybacks | $213M | $169M | $10.6M | $34.4M | $20.2M | $690M | $199M | $16.1M | $340M | $342M |
| Dividends paid | $1.3B | $1.3B | $1.3B | $2.6B | $2.7B | $2.5B | $2.1B | $2.0B | $2.0B | $2.1B |
| Dividends and buybacks | $1.5B | $1.4B | $1.3B | $2.6B | $2.7B | $3.2B | $2.3B | $2.0B | $2.3B | $2.4B |
| Balance sheet | ||||||||||
| Cash and short-term investments | $2.9B | $2.8B | $6.3B | $5.9B | $8.7B | $7.0B | $4.0B | $3.0B | $2.6B | $3.7B |
| Total debt | — | $9.3B | $51.9B | $46.9B | $41.8B | $35.7B | $32.9B | $32.0B | $30.2B | $30.6B |
| Current assets | — | $10.1B | $27.0B | $22.8B | $24.5B | $21.3B | $18.0B | $16.9B | $16.9B | $19.4B |
| Current liabilities | — | $6.9B | $23.0B | $20.0B | $16.0B | $17.6B | $18.6B | $15.3B | $16.8B | $17.8B |
| Inventory | — | $2.0B | $8.3B | $7.0B | $6.8B | $7.0B | $7.4B | $8.0B | $8.1B | $8.8B |
| Property and equipment, net | — | $5.0B | $12.0B | $12.8B | $13.1B | $13.0B | $12.7B | — | — | — |
| Goodwill | — | $9.7B | $38.3B | $37.0B | $36.4B | $36.2B | $36.0B | $35.8B | $35.6B | $36.4B |
| Intangible assets | — | $9.5B | $42.9B | $38.4B | $35.3B | $31.4B | $32.1B | $28.3B | $24.3B | $21.4B |
| Total assets | — | $38.6B | $124.5B | $118.1B | $116.5B | $108.2B | $104.8B | $99.9B | $95.4B | $97.3B |
| Total liabilities | — | $19.6B | $77.7B | $74.6B | $69.8B | $61.5B | $57.1B | $51.8B | $48.9B | $50.7B |
| Shareholders' equity | $17.4B | $18.8B | $46.8B | $43.5B | $46.7B | $46.7B | $47.7B | $48.1B | $46.4B | $46.6B |
| Margins | ||||||||||
| Gross margin | 67.7% | 72.0% | 68.9% | 66.9% | 68.9% | 69.0% | 69.1% | 66.5% | 65.5% | 65.1% |
| Operating margin | 9.0% | 13.7% | 11.3% | 3.1% | 15.9% | 12.9% | 12.2% | 5.0% | 7.5% | 0.1% |
| EBITDA margin | 18.9% | 23.9% | 23.1% | 20.8% | 33.4% | 29.3% | 28.7% | 22.1% | 24.1% | 16.1% |
| Net margin | 6.6% | 10.6% | 6.4% | 1.3% | 11.8% | 6.4% | 7.9% | 3.4% | 2.4% | −3.4% |
| FCF margin | 11.5% | 17.6% | 12.0% | 16.5% | 28.1% | 28.0% | 20.8% | 12.7% | 18.7% | 19.2% |
| Returns | ||||||||||
| Return on capital | — | 7.4% | 2.3% | 0.9% | 6.0% | 4.1% | 4.0% | 1.9% | 2.0% | 0.0% |
| Return on capital employed | — | 6.9% | 2.1% | 0.9% | 4.8% | 4.5% | 4.2% | 1.8% | 2.9% | 0.1% |
| Return on equity | 6.1% | 9.3% | 3.7% | 0.9% | 7.9% | 4.4% | 5.0% | 2.1% | 1.5% | −2.2% |
| Return on assets | — | 4.4% | 1.5% | 0.3% | 3.0% | 1.8% | 2.2% | 1.0% | 0.7% | −1.0% |
| Return on tangible equity | 6.1% | — | — | — | — | — | — | — | — | — |
| Growth | ||||||||||
| Revenue growth | — | −0.1% | 18.4% | 60.1% | −0.4% | 5.3% | −6.4% | −0.8% | 1.9% | −0.5% |
| Net income growth | — | 58.9% | −27.7% | −66.6% | 771.4% | −42.3% | 14.3% | −57.4% | −29.0% | −242.8% |
| EPS growth | — | 58.7% | −41.2% | −79.4% | 766.9% | −42.4% | 14.8% | −57.7% | −30.1% | −245.5% |
| FCF growth | — | 52.1% | −19.3% | 120.8% | 70.0% | 4.9% | −30.6% | −39.4% | 50.1% | 2.2% |
| Share count change | — | 0.1% | 22.9% | 62.0% | 0.5% | 0.2% | −0.5% | 0.7% | 1.6% | −1.9% |
| Financial health | ||||||||||
| Net debt / EBITDA | — | 1.7x | 10.4x | 6.5x | 3.3x | 3.1x | 3.4x | 4.5x | 3.8x | 5.6x |
| Debt / equity | — | 0.5x | 1.1x | 1.1x | 0.9x | 0.8x | 0.7x | 0.7x | 0.7x | 0.7x |
| Interest coverage | 20.6x | 24.1x | 4.9x | 0.7x | 3.9x | 3.8x | 4.2x | 1.8x | 2.5x | 0.0x |
| Current ratio | — | 1.5x | 1.2x | 1.1x | 1.5x | 1.2x | 1.0x | 1.1x | 1.0x | 1.1x |
| Quick ratio | — | 1.2x | 0.8x | 0.8x | 1.1x | 0.8x | 0.6x | 0.6x | 0.5x | 0.6x |
| Capital allocation | ||||||||||
| Capex / revenue | 3.6% | 3.8% | 3.7% | 3.9% | 3.5% | 3.5% | 3.5% | 4.1% | 4.4% | 3.9% |
| Payouts / FCF | 82.5% | 51.7% | 57.5% | 52.8% | 31.7% | 36.1% | 36.6% | 53.5% | 41.4% | 42.0% |
| Quality scores | ||||||||||
| Piotroski F-score | — | — | 3.0 | 5.0 | 8.0 | 6.0 | 7.0 | 5.0 | 5.0 | 5.0 |
| Altman Z'' | — | 3.2 | 1.3 | 1.2 | 1.8 | 1.6 | 1.4 | 1.5 | 1.4 | 1.2 |
| Accruals ratio | — | −4.5% | −2.1% | −4.7% | −5.1% | −7.1% | −4.6% | −3.9% | −6.4% | −8.2% |
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
The original documents every number on this page comes from.
Source: SEC EDGAR XBRL filings (CIK 0001395064). Data updated November 1, 2026. Quarterly fourth quarters are the full year minus the first nine months. Filed in JPY under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. Per-share figures are per US-listed share (1 ADS = 0.50 ordinary shares). For information only — not investment advice. Check the original filings before relying on any figure.
Do you want to get alerts?
An email when your companies or sectors make a big move at the close. Free, and you leave with one click.
Do you want to turn on or review your alerts?
Add companies or sectors, change the move that triggers an email, or pause what you no longer need.
We would like to use Google Analytics and Amplitude cookies to count visits and see how pages are used, including anonymised session recordings, so we can improve Stoqly. They are only set if you accept. No ads, no selling of data. Cookie policy
